RECURSION PHARMACEUTICALS, INC. Capital Expenditures Incurred but Not yet Paid
RECURSION PHARMACEUTICALS, INC. (RXRX) reported Capital Expenditures Incurred but Not yet Paid of $300.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2026-08-05
- RECURSION PHARMACEUTICALS, INC. capital expenditures incurred but not yet paid for the quarter ending 2026-06-30 was $300.00K.
- RECURSION PHARMACEUTICALS, INC. capital expenditures incurred but not yet paid for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- RECURSION PHARMACEUTICALS, INC. capital expenditures incurred but not yet paid for the quarter ending 2025-12-31 was -$29.00K, a 114.29% decline year-over-year.
- RECURSION PHARMACEUTICALS, INC. capital expenditures incurred but not yet paid for the quarter ending 2025-09-30 was -$234.00K.
- RECURSION PHARMACEUTICALS, INC. capital expenditures incurred but not yet paid for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- RECURSION PHARMACEUTICALS, INC. capital expenditures incurred but not yet paid for fiscal 2024 was $439.00K, a 82.00% decline from fiscal 2023.
- RECURSION PHARMACEUTICALS, INC. capital expenditures incurred but not yet paid for fiscal 2023 was $2.44M, a 312.69% increase from fiscal 2022.
- RECURSION PHARMACEUTICALS, INC. capital expenditures incurred but not yet paid for fiscal 2022 was $591.00K, a 92.37% decline from fiscal 2021.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|
| 2026-06-30 | $300.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $300.00K 10-Q · filed 2026-08-05 | $271.00K derived: sum of 3 quarters · filed 2026-08-05 | $37.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-06 | -$29.00K derived: sum of 2 quarters · filed 2026-05-06 | -$263.00K derived: sum of 3 quarters · filed 2026-05-06 | -$1.15M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$29.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$263.00K derived: sum of 2 quarters · filed 2026-02-25 | -$1.15M derived: sum of 3 quarters · filed 2026-08-05 | $0.00 10-K · filed 2026-02-25 |
| 2025-09-30 | -$234.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$1.12M derived: sum of 2 quarters · filed 2026-08-05 | $29.00K 10-Q · filed 2025-11-05 | $232.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$883.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $263.00K 10-Q · filed 2026-08-05 | $466.00K derived: sum of 3 quarters · filed 2026-08-05 | $153.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $1.15M 10-Q · filed 2026-05-06 | $1.35M derived: sum of 2 quarters · filed 2026-05-06 | $1.04M derived: sum of 3 quarters · filed 2026-05-06 | $1.50M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $203.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$110.00K derived: sum of 2 quarters · filed 2026-02-25 | $359.00K derived: sum of 3 quarters · filed 2026-02-25 | $439.00K 10-K · filed 2026-02-25 |
| 2024-09-30 | -$313.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $156.00K derived: sum of 2 quarters · filed 2025-11-05 | $236.00K 10-Q · filed 2025-11-05 | $2.67M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $469.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $549.00K 10-Q · filed 2025-08-05 | $2.99M derived: sum of 3 quarters · filed 2026-02-25 | $2.98M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $80.00K 10-Q · filed 2025-05-05 | $2.52M derived: sum of 2 quarters · filed 2026-02-25 | $2.51M derived: sum of 3 quarters · filed 2026-02-25 | $2.27M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $2.44M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $2.43M derived: sum of 2 quarters · filed 2026-02-25 | $2.19M derived: sum of 3 quarters · filed 2026-02-25 | $2.44M 10-K · filed 2026-02-25 |
| 2023-09-30 | -$6.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$244.00K derived: sum of 2 quarters · filed 2024-11-06 | $0.00 10-Q · filed 2024-11-06 | -$2.50M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | -$238.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $6.00K 10-Q · filed 2024-08-08 | -$2.50M derived: sum of 3 quarters · filed 2025-02-28 | -$3.58M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $244.00K 10-Q · filed 2024-05-09 | -$2.26M derived: sum of 2 quarters · filed 2025-02-28 | -$3.34M derived: sum of 3 quarters · filed 2025-02-28 | -$3.49M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | -$2.50M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | -$3.58M derived: sum of 2 quarters · filed 2025-02-28 | -$3.74M derived: sum of 3 quarters · filed 2025-02-28 | $591.00K 10-K · filed 2025-02-28 |
| 2022-09-30 | -$1.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$1.24M derived: sum of 2 quarters · filed 2023-11-09 | $3.09M 10-Q · filed 2023-11-09 | $10.43M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | -$154.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $4.17M 10-Q · filed 2023-08-08 | $11.51M derived: sum of 3 quarters · filed 2024-02-29 | $11.16M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $4.33M 10-Q · filed 2023-05-08 | $11.66M derived: sum of 2 quarters · filed 2024-02-29 | $11.31M derived: sum of 3 quarters · filed 2024-02-29 | $11.37M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $7.34M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $6.99M derived: sum of 2 quarters · filed 2024-02-29 | $7.04M derived: sum of 3 quarters · filed 2024-02-29 | $7.75M 10-K · filed 2024-02-29 |
| 2021-09-30 | -$350.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$292.00K derived: sum of 2 quarters · filed 2022-11-08 | $413.00K 10-Q · filed 2022-11-08 | $1.77M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $58.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $763.00K 10-Q · filed 2022-08-09 | $2.12M derived: sum of 3 quarters · filed 2023-02-27 | $2.15M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $705.00K 10-Q · filed 2022-05-10 | $2.06M derived: sum of 2 quarters · filed 2023-02-27 | $2.09M derived: sum of 3 quarters · filed 2023-02-27 | $2.10M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $1.36M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $1.39M derived: sum of 2 quarters · filed 2023-02-27 | $1.40M derived: sum of 3 quarters · filed 2023-02-27 | $1.40M 10-K · filed 2023-02-27 |
| 2020-09-30 | $31.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $42.00K derived: sum of 2 quarters · filed 2021-11-10 | $42.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $11.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | $11.00K 10-Q · filed 2021-08-13 | ||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-12 | |||
| 2019-12-31 | $0.00 10-K · filed 2022-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |